Accendra Health (ACH) Reports 2025 Revenue of $2.8B and Shift Toward Core Home-Based Care

4 weeks ago 2

Maham Fatima

Tue, February 24, 2026 astatine 8:32 AM CST 2 min read

Accendra Health Inc. (NYSE:ACH) is 1 of the astir undervalued penny stocks to bargain close now. On February 19, Accendra Health reported full-year 2025 gross of astir $2.8 billion, which was a 3% year-over-year increase. Despite this growth, Q4 adjusted EBITDA fell to $90 cardinal from $102.5 cardinal successful the anterior year, bringing the yearly full to $375 million. This advancement was supported by the merchantability of the company’s erstwhile products and healthcare services business, allowing the steadfast to absorption connected its halfway home-based attraction brands, Byram and Apria.

Accendra Health Inc. (NYSE:ACH) faces important headwinds heading into 2026, chiefly owed to the nonaccomplishment of a ample commercialized payer, which is expected to trim gross by $300 million. Consequently, 2026 gross guidance is acceptable astatine $2.55 to $2.65 billion, with adjusted EBITDA projected astatine $335 to $355 million. Management besides noted challenges from inflationary merchandise costs and stranded costs related to the caller divestiture.

Accendra Health (ACH) Reports 2025 Revenue of $2.8B and Shift Toward Core Home-Based Care

These factors are expected to effect successful a weaker H1 2026, with lone 40% of the year’s adjusted EBITDA anticipated during that play arsenic cost-reduction initiatives ramp up. Strategic priorities for the coming twelvemonth halfway connected indebtedness simplification and operational ratio done technology, specified arsenic the MyApria app. The CFO projected escaped currency travel of astatine slightest $100 cardinal for 2026.

Accendra Health Inc. (NYSE:ACH), unneurotic with its subsidiaries, operates arsenic a healthcare solutions institution successful the US. It offers a scope of products & services for in-home attraction & transportation for diabetes treatment, location respiratory therapy, and obstructive slumber apnea treatment.

While we admit the imaginable of ACH arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you’re looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 10 Most Profitable Undervalued Stocks to Buy and 11 Best Mining Stocks to Buy According to Wall Street.

Disclosure: None.

Read Entire Article